Check-Cap (NASDAQ:CHEK) Coverage Initiated at StockNews.com

Stock analysts at StockNews.com started coverage on shares of Check-Cap (NASDAQ:CHEK) in a report released on Wednesday. The firm set a “sell” rating on the medical research company’s stock.

Check-Cap Stock Down 0.7 %

CHEK opened at $1.48 on Wednesday. Check-Cap has a twelve month low of $1.13 and a twelve month high of $3.94. The company has a fifty day moving average of $1.69 and a 200-day moving average of $2.01. The stock has a market cap of $8.66 million, a PE ratio of -0.49 and a beta of 0.36.

Check-Cap Company Profile

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.